Skip to main content
. 2021 Jun 28;6(6):546–563. doi: 10.1016/j.jacbts.2021.01.006

Figure 4.

Figure 4

B-Cell and Plasma Cell Depletion Therapies

These therapies target surface receptors that are pan markers of B cells (CD20, CD19, CD22) and plasma cells (CD38, CD19, SLAMF7, BCMA). The impact of these therapies on atherosclerosis is unknown but maybe governed by the B cell subtypes/plasma cells that are depleted.